Introduction Taking folic acid containing supplements prior to and during early pregnancy reduces the risk of neural tube defects. Neural tube defects occur prior to 28 days postconception, after which, there is no proven benefit of continuing to take folic acid. However, many women continue to take folic acid containing supplements throughout the pregnancy. At higher intakes, folic acid is not converted to its active form and accumulates in circulation as unmetabolised folic acid (UMFA). Recently, concerns have been raised about possible links between late gestation folic acid supplementation and childhood allergy, metabolic disease and autism spectrum disorders. We aim to determine if removing folic acid from prenatal micronutrient supplements after 12 weeks gestation reduces circulating levels of maternal UMFA at 36 weeks gestation.
Methods and analysis This is a parallel-design, double-blinded randomised controlled trial. Women ≥12 and <16 weeks’ gestation with a singleton pregnancy and able to give informed consent are eligible to participate. Women (n=100; 50 per group) will be randomised to receive either a micronutrient supplement containing 0.8 mg of folic acid or a micronutrient supplement without folic acid daily from enrolment until delivery. The primary outcome is plasma UMFA concentration at 36 weeks gestation. Secondary outcomes include red blood cell folate and total plasma folate concentration. We will assess whether there is a difference in mean UMFA levels at 36 weeks gestation between groups using linear regression with adjustment for baseline UMFA levels and gestational age at trial entry. The treatment effect will be described as a mean difference with 95% CI.
Ethics and dissemination Ethical approval has been granted from the Women’s and Children’s Health Network Research Ethics Committee (HREC/19/WCHN/018). The results of this trial will be presented at scientific conferences and published in peer-reviewed journals.
Trial registration number ACTRN12619001511123.
- nutrition & dietetics
- public health
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
We will determine if discontinuing folic acid supplementation after 12 weeks of gestation results in lower levels of unmetabolised folic acid.
Unmetabolised folic acid is a biomarker of excess folic, and has been associated with a number of adverse pregnanacy outocomes.
This study is not powered to determine the effect of continuing folic acid supplements after the first trimester on clinical outcomes.
The study findings will be generalisable to countries which like Australia have mandatory folic acid fortification.
This research will inform the need for larger trials to determine if folic acid beyond the first trimester leads to adverse maternal and infant health outcomes.
Evidence from randomised controlled trials1 2 and a large public health intervention3 showed that taking folic acid containing supplements prior to and during early pregnancy reduces the incidence of neural tube defects (NTD). Based on these findings, public health agencies around the world issued recommendations advising women to take folic acid supplements prior to conception and during early pregnancy.4 For example, in Australia, the government recommends that women trying to become pregnant take a folic acid supplement of 0.5 mg/day 12 weeks prior to conceiving and for the first 12 weeks of pregnancy.5
The neural tube closes in the first month of pregnancy, beyond this time there is no proven benefit of taking folic acid.6 However, many women continue to take folic acid as part of a prenatal vitamin and mineral supplement throughout pregnancy.7 In Australia, for example, a randomised controlled trial of pregnant women showed that more than 80% of women were taking a prenatal supplement containing folic acid at some time during their pregnancy,8 with the market leading supplement containing 0.8 mg of folic acid. Furthermore, almost 80 countries, including Australia, have mandated the addition of folic acid to food staples, typically wheat flour, to reduce NTDs in unplanned pregnancies.9 As such, the combination of food fortification along with prenatal supplement use may expose women and their fetus to excessive amounts of folic acid.
There is emerging evidence that higher intakes of folic acid in pregnancy may have negative health effects on the offspring including autism spectrum disorders10–12 and insulin resistance.13 An increased risk of childhood allergic disease is chief among these concerns with several studies reporting an inverse association with folic acid14–24 However, results are inconsistent and some studies report no relationship between folic acid intake and allergy outcomes in offspring25–27 or a reduction in risk of allergic disease.28 These studies vary greatly in regard to the timing and measurement of exposure and only one study differentiated between maternal total plasma folate and maternal plasma unmetabolised folic acid (UMFA).29
Folic acid is the synthetic form of the vitamin folate that is used in supplements and fortified foods because of its high bioavailability and stability compared with naturally occurring folate in food.30 Once consumed, folic acid must be converted into an active form, 5-methyltetrahydrofolate.31 At higher intakes folic acid is not converted to its active form and accumulates in plasma as UMFA.32 Circulating UMFA has been proposed as a biomarker of excess folic acid intake.33 Without proven benefit and with the suggestion of harm, the amount of folic acid in prenatal supplements may need to be reduced after the first trimester. We aim to determine if removing folic acid from prenatal multivitamin supplements after the first trimester (12 weeks gestation) reduces the accumulation of maternal UMFA measured at 36 weeks gestation.
Removing folic acid from prenatal supplements after 12 weeks of gestation will limit the accumulation of UMFA in maternal plasma at 36 weeks of gestation.
Methods and analysis
A multicentre two-arm parallel design, double-blinded randomised controlled trial.
The sponsoring institution and Trial Coordinating Centre is the South Australian Health and Medical Research Insititute (SAHMRI) based at the Women’s and Children’s Hospital (WCH). We will also seek approval to conduct the trial at Flinders Medical Centre (FMC), Adelaide, South Australia.
Participants are pregnant women with a singleton pregnancy enrolled between ≥12 and <16 weeks gestation. Enrolment commenced on 18 December 2019 and recruitment is ongoing. Data collection will continue through to May 2021.
To be eligible for participation women must be:
Carrying a singleton pregnancy ≥12 and <16 weeks gestation.
Currently taking a folic acid containing supplement and planning to continue this throughout pregnancy.
Able to give informed consent.
Women will be ineligible for trial participation if they meet any the following criteria:
Carrying a fetus with a confirmed or suspected fetal abnormality.
Unwilling to cease current folic acid containing supplement/s.
Past history of an NTD affected pregnancy.
Currently taking medication known to interfere with folate metabolism (eg, methotrexate, sulphasalazine, anticonvulsants, antimalarials or barbiturates).
Known haemolytic anaemia or haemoglobinopathy.
Known to carry the TT variant of the methylene tetrahydrofolate reductase gene (MTHFR C77T) polymorphism.
Intolerance or allergy to prenatal vitamin and mineral supplements.
Participating women will be randomised to receive either a micronutrient supplement in tablet form, containing 0.8 mg folic acid (the dose in the most commonly used supplement in Australia or an identical micronutrient supplement containing no folic acid. The composition of micronutrients within the intervention and control supplements are formulated to approximate leading brands of prenatal micronutrient supplements available in Australia (table 1). Intervention and control supplements are identical in size, shape, colour and packaging and only differ in the removal of folic acid from the intervention supplement. Women will be asked to consume one supplement per day from enrolment (≥12 and <16 weeks of gestation) until delivery.
Manufacture of study supplements
Intevention and control supplements are manufactured in a licensed facility in accordance with the Code of Good Manufacturing Practice (GMP) for Medicinal Products and have been donated to the trial by Factors Group of Companies, Coquitlam, British Columbia, Canada. The supplements are packaged and labelled in accordance with GMP including an individual product identifier, batch number, expiry date and the statement ‘for clinical trial use only’. The pharmacist or the investigator’s designee maintains accurate records of the dispensing of study product. Unused study supplements will be destroyed in compliance with applicable regulations.
Monitoring adherence to study treatment
Research personnel will maintain regular contact with participating women to monitor and encourage supplement adherence and study compliance and answer any questions as they arise. At each contact, women will be asked if they have missed any supplements in the last week and if so, how many have been missed. Women will be asked to return unused supplements at the final study visit (36 weeks’ gestation) and the proportion of supplements returned will serve as the primary measure of compliance. A woman will be classified as compliant if she takes greater than 80% of her study supplements. At this visit women will be issued with enough supplements to last until the delivery of their baby.
The primary outcome is maternal plasma UMFA concentration at 36 weeks gestation.
Maternal plasma total and red blood cell folate levels at 36 weeks’ gestation.
Gestational age at birth, birth weight, birth length, birth head circumference.
Neonatal complications requiring admission to the neonatal unit.
Pregnancy complications requiring hospital admission.
Serious adverse events defined as: maternal or fetal (>20 weeks) deaths, fetal loss (<20 weeks), maternal or neonatal admissions to intensive care and major congenital anomalies.
Women will be randomised and asked to cease their current prenatal supplements immediately and for the duration of the study. At enrolment, following informed consent and prior to commencement of the study treatment, research personnel will collect baseline clinical and demographic data including: contact details, self-reported ethnicity, gravida, parity, age, supplement and prescription drug use, weight, height, highest level of education, occupation and smoking status. Maternal dietary intakes of folate and other one-carbon nutrients during early and late pregnancy will be collected with the use of an 80-item semiquantitative Food-Frequency Questionnaire—Dietary Questionnaire for Epidemiological Studies (V.3.2).34 A 10 mL venous blood sample will be collected by venepuncture to assess UMFA, folate status and full blood count. The time the woman last ate and drank as well as the time her last supplement was taken will be recorded. Research personnel will contact the participant 1 week following the enrolment visit and then monthly to ensure adherence and record adverse events (figure 1). At 36 weeks’ gestation participating women will attend a clinic appointment for collection of venous blood sample for UMFA and folate analysis and full blood count. Participants will be asked to return unused supplements which will be counted as a measure of compliance. The Food-Frequency Questionnaire will be repeated and women will be given enough supplements to last the remainder of their pregnancy. Following delivery, research personnel will extract details of pregnancy, labour and birth from the woman and her baby’s medical records. Blood samples will be analysed for UMFA according to established methods.35 Plasma folate (nmol/L) and erythrocyte folate (nmol/L) concentrations will be determined using the folate microbiological assay harmonised by the Centers for Disease Control and Prevention.36
A sample size of 90 women (45 per group) will provide >90% power to detect a standardised difference in mean UMFA concentration at 36 weeks gestation between groups of 0.60 (two-tailed alpha =0.05, correlation between UMFA concentrations at baseline and 36 weeks of gestation=0.60).29 Calculations were performed based on a standardised mean difference (mean difference divided by SD of outcome at 36 weeks gestation) due to considerable variability in the literature in the reported SD for UMFA concentration in pregnancy.16 29 A standardised mean difference of 0.60 represents a medium effect size and would demonstrate biologically excessive folic acid consumption. To allow for 10% lost to follow-up, we will randomise 50 women per group.
Pregnant women will be recruited through a combination of flyers,posters, a digital media campaign and through in-person recruitment at antenatal clinics. Women who meet eligibility criteria and agree to participate are invited to attend an enrolment appointment at our research clinics at the WCH or FMC, Adelaide between 12 and 16 weeks gestation.
Participants will be randomised using a secure web-based randomisation service. Allocation will follow a computer-generated randomisation schedule using balanced variable block sizes, prepared by an independent statistician who is not involved with trial participants or data analysis. A unique four-digit study identification number and a coloured coded study pack are assigned to each participant. Stratification will be by gestational age at trial entry 12 to ≤14 weeks or >14 to 16 weeks gestation.
The independent unblinded statistician (not involved in any other way in the trial) allocated two colours to the intervention group and two colours to the control group. Supplements were subsequently packaged and labelled with a colour by two unblinded staff members who have no other involvement in the trial. Research personnel, participants and their family, care providers, outcome assessors and data analysts remain blinded to colour allocation and therefore randomisation group.
The intervention and control supplements are identical in size, shape, colour, packaging and labelling and uniquely identified by the coloured product identification label (yellow, pink, blue or green) only. The randomisation code for an individual participant may be unblinded by the independent statistician in the event of an emergency.
Data collection and trial management
Data are collected by trained research personnel and entered directly into an electronic case report form with password protection and defined user-level access Research Electronic Data Capture (REDCap). A record of all women approached, screened for eligibility and consented will be recorded.37 Once consented and randomised, REDCap has been designed to automatically calculate study milestones for each participant. This information is readily available for clinical trial staff to enable scheduling of appointments and sample collection. Summary reports including screening data, enrolment, appointment attendance, sample collection, serious adverse events and study completion are generated from REDCap and reviewed at monthly trial steering committee meetings. Electronic data are stored on secure servers at South Australia Health and Medical Research Institute and released only to persons authorised to receive those data.
Data and safety monitoring
We do not anticipate any serious adverse events related to participation in this trial. Regardless, an independent (blinded) clinician will review all serious adverse events and determine whether there is any likelihood that involvement in the trial could have contributed to the event. Determinations of causality will be made from medical records retrieved for this purpose. All serious adverse events will be captured and reported to the Human Research Ethics Committee.
Statistical analyses will be performed on an intention-to-treat basis according to a pre-specified statistical analysis plan. For the primary outcome, we will assess whether there is a difference in mean UMFA levels at 36 weeks gestation between groups using linear regression, with adjustment for baseline UMFA and the stratification variable gestational age at trial entry (12 to ≤14 weeks or >14 weeks). The treatment effect will be described as a mean difference with 95% CI. Secondary outcomes will be analysed using linear and logistic regression models for continuous and binary outcomes, respectively, again with adjustment for gestational age at trial entry. Safety outcomes will be compared between groups using Fisher exact tests. In all analyses, a two-sided p<0.05 will be taken to indicate statistical significance.
Ethics and dissemination
Human Research Ethics Approval
This protocol, the informed consent and participant information document and all participant communication have been approved by the Women’s and Children’s Health Network Research Ethics Committee (HREC) (HREC/19/WCHN/018) and Governance (SSA/19/WCHN/080). Governance approval has also been obtained from FMC. Any subsequent modifications will be reviewed and approved by the HREC and governance of each study site. The study will be conducted in compliance with the current approved version of the protocol. Any change to the protocol document or informed consent form that affects the scientific intent, study design, patient safety or may affect a participant’s willingness to continue participation in the study will be considered a major amendment. All such amendments will be submitted to the HREC for approval. Any other changes to the protocol (such as administrative changes to dates and study personnel) will be considered minor amendments and will be notified to the HREC as appropriate.
Participant confidentiality is strictly held in trust by the participating investigators, research staff and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clinical information relating to participants. Regulatory authorities may inspect all documents and records required to be maintained by the Investigator, including but not limited to, medical records for the women and/or infants in this study subject to individuals having obtained approval/clearance through State/National Governments and HREC as required by local laws. Clinical information will not be released without written permission of the parent, except as necessary for monitoring by HREC or regulatory agencies.
Patient and public involvement
The study was supported by a consumer advisory group which provided input to the protocol. A Consumer representative from our SAHMRI Women and Kids Consumer Advisory Group partnered with us for the design of the study, informational material to support the intervention, and the burden of the intervention from the participant’s perspective. We will meet with the consumer representative for this trial and the full Consumer Advisory group on a regular basis for the duration of the study. At the end of the study, the consumer advisory group will be given the opportunity to comment on the findings and contribute to the dissemination plan.
Study findings will be submitted for peer-reviewed publication and for presentation at appropriate local and international conferences. In addition, study findings will be disseminated to participants through a one-page lay summary. Results will be made available to the wider community through social media avenues and the SAHMRI website.
Contributors KPB, TG, MM, DP and MS conceived the trial and proposed the trial design; TS advised on sample size calculations, trial design and analysis; SW and TG designed the prenatal supplement and had it manufactured; DS advised on analytical methodology; DS, TG and KPB drafted the protocol, all authors contributed to refinement of the study and approved the final manuscript.
Funding This study is sponsored by the South Australian Health and Medical Research Institute (Adelaide, Australia). This study is supported by grants in aid from the Women’s and Children’s Hosptial Foundation (Best_WCHFG_2020). An Ella McKnight Scholarship from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists supports MS. KPB is supported by a Women’s and Children’s Hospital Foundation, MS McLeod Postdoctoral Research Fellowship. DS is supported by the Australian Government Research Training Program Scholarship from The University of Adelaide. The study product is donated by Factors Group of Companies, Coquitlam, British Columbia, Canada.
Disclaimer The funder/s have no role in the study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication and have no authority over any of these activities.
Competing interests MM reports that she has a financial relationship outside the submitted work with Trajan Nutrition as a member of the board. SW is a consultant for the Factors Group of Companies. DS, TG, DP, TS MS and KPB have nothing to disclose.
Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.